Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome. - Hernandez-Jerez AF; Adriaanse P; Aldrich A; Berny P; Coja T; Duquesne S; Focks A; Millet M; Pelkonen O; Pieper S; Tiktak A; Topping CJ; et al. (EFSA journal. European Food Safety Authority, 2023)